Dabrafenib Plus Trametinib Versus Anti-Pd-1 Monotherapy As Adjuvant Therapy in BRAF V600-mutant Stage III Melanoma after Definitive Surgery: a Multicenter, Retrospective Cohort Study Xue Bai , Ahmed Shaheen , Charlotte Grieco , Paolo D. d'Arienzo , Florentia Mina , Juliane A. Czapla , Aleigha R. Lawless , Eleonora Bongiovanni , Umberto Santaniello , Helena Zappi , Dominika Dulak , Andrew Williamson , Rebecca Lee , Avinash Gupta , Caili Li , Lu Si , Martina Ubaldi , Naoya Yamazaki , Dai Ogata , Rebecca Johnson , Benjamin C. Park , Seungyeon Jung , Gabriele Madonna , Juliane Hochherz , Yoshiyasu Umeda , Yasuhiro Nakamura , Christoffer Gebhardt , Lucia Festino , Mariaelena Capone , Paolo Antonio Ascierto , Douglas B. Johnson , Serigne N. Lo , Georgina L. Long , Alexander M. Menzies , Kenjiro Namikawa , Mario Mandala , Jun Guo , Paul Lorigan , Yana G. Najjar , Andrew Haydon , Pietro Quaglino , Genevieve M. Boland , Ryan J. Sullivan , Andrew J. S. Furness , Ruth Plummer , Keith T. Flaherty ECLINICALMEDICINE（2023）
Key words
Adjuvant therapy, BRAF V600 mutation, Melanoma, PD-1, Dabrafenib/trametinib
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
